scholarly journals TArget-Responsive Subcellular Catabolism Analysis for Early-stage Antibody-Drug Conjugates Screening and Assessment

2020 ◽  
Author(s):  
Hua Sang ◽  
Jiali Liu ◽  
Fang Zhou ◽  
Xiaofang Zhang ◽  
Jingwei Zhang ◽  
...  
Keyword(s):  
Quality Assessment ◽  
Therapeutic Efficacy ◽  
High Throughput Screening ◽  
Early Stage ◽  
Cellular Level ◽  
Drug Conjugates ◽  
Therapeutic Outcomes ◽  
Lysosomal Proteolysis

<p></p><p>Key events including antibody-antigen affinity, ADC internalization, trafficking and lysosomal proteolysis-mediated payload release combinatorially determine the therapeutic efficacy and safety for ADCs. Nevertheless, a universal technology that efficiently and conveniently evaluates the involvement of these above elements to ADC payload release and hence the final therapeutic outcomes for mechanistic studies and quality assessment is lacking. Considering the plethora of ADC candidates under development owing to the ever-evolving linker and drug chemistry, we developed a TArget-Responsive Subcellular Catabolism (TARSC) approach that measures catabolites kinetics for given ADCs and elaborates how each individual step ranging from antigen binding to lysosomal proteolysis affects ADC catabolism by targeted interferences. Using a commercial and a biosimilar ado-trastuzumab emtansine (T-DM1) as model ADCs, we recorded unequivocal catabolites kinetics for the two T-DM1s in the presence and absence of the targeted interferences. Their negligible differences in TARSC profiles fitting with their undifferentiated therapeutic outcomes suggested by <i>in vitro</i> viability assays and <i>in vivo</i> tumor growth assays, highlighting TARSC analysis as a good indicator of ADC efficacy and bioequivalency. Lastly, we demonstrated the use of TARSC in assessing payload release efficiency for a new Trastuzumab-toxin conjugate. Collectively, we demonstrated the use of TARSC in characterizing ADC catabolism at (sub)cellular level, and in systematically depicting whether given target proteins affect ADC payload release and hence therapeutic efficacy. We anticipate its future use in high-throughput screening, quality assessment and mechanistic understanding of ADCs for drug R&D before proceeding to costly <i>in vivo</i> experiments.</p><br><p></p>

scholarly journals TArget-Responsive Subcellular Catabolism Analysis for Early-stage Antibody-Drug Conjugates Screening and Assessment

2020 ◽  
Author(s):  
Hua Sang ◽  
Jiali Liu ◽  
Fang Zhou ◽  
Xiaofang Zhang ◽  
Jingwei Zhang ◽  
...  
Keyword(s):  
Quality Assessment ◽  
Therapeutic Efficacy ◽  
High Throughput Screening ◽  
Early Stage ◽  
Cellular Level ◽  
Drug Conjugates ◽  
Therapeutic Outcomes ◽  
Lysosomal Proteolysis

<p></p><p>Key events including antibody-antigen affinity, ADC internalization, trafficking and lysosomal proteolysis-mediated payload release combinatorially determine the therapeutic efficacy and safety for ADCs. Nevertheless, a universal technology that efficiently and conveniently evaluates the involvement of these above elements to ADC payload release and hence the final therapeutic outcomes for mechanistic studies and quality assessment is lacking. Considering the plethora of ADC candidates under development owing to the ever-evolving linker and drug chemistry, we developed a TArget-Responsive Subcellular Catabolism (TARSC) approach that measures catabolites kinetics for given ADCs and elaborates how each individual step ranging from antigen binding to lysosomal proteolysis affects ADC catabolism by targeted interferences. Using a commercial and a biosimilar ado-trastuzumab emtansine (T-DM1) as model ADCs, we recorded unequivocal catabolites kinetics for the two T-DM1s in the presence and absence of the targeted interferences. Their negligible differences in TARSC profiles fitting with their undifferentiated therapeutic outcomes suggested by <i>in vitro</i> viability assays and <i>in vivo</i> tumor growth assays, highlighting TARSC analysis as a good indicator of ADC efficacy and bioequivalency. Lastly, we demonstrated the use of TARSC in assessing payload release efficiency for a new Trastuzumab-toxin conjugate. Collectively, we demonstrated the use of TARSC in characterizing ADC catabolism at (sub)cellular level, and in systematically depicting whether given target proteins affect ADC payload release and hence therapeutic efficacy. We anticipate its future use in high-throughput screening, quality assessment and mechanistic understanding of ADCs for drug R&D before proceeding to costly <i>in vivo</i> experiments.</p><br><p></p>

scholarly journals Edwardsiella tarda Eta1, anIn Vivo-Induced Antigen That Is Involved in Host Infection

2012 ◽  
Vol 80 (8) ◽  
pp. 2948-2955 ◽  
Author(s):  
Yun Sun ◽  
Wen-Jiang Zheng ◽  
Yong-Hua Hu ◽  
Bo-Guang Sun ◽  
Li Sun
Keyword(s):  
Early Stage ◽  
Paralichthys Olivaceus ◽  
Cellular Level ◽  
Host Cells ◽  
Edwardsiella Tarda ◽  
Pcr Analysis ◽  
Logarithmic Phase ◽  
Content Type

ABSTRACTEdwardsiella tarda, a Gram-negative bacterium, is a severe fish pathogen that can also infect humans. In this study, we identified, viain vivo-induced antigen technology, anE. tardaantigen, Eta1, and analyzed its function in a Japanese flounder (Paralichthys olivaceus) model. Eta1 is composed of 226 residues and shares homology with putative bacterial adhesins. Quantitative real-time reverse transcriptase (RT)-PCR analysis indicated that when culturedin vitro,eta1expression was growth phase dependent and reached maximum at mid-logarithmic phase. During infection of flounder lymphocytes,eta1expression was drastically increased at the early stage of infection. Compared to the wild type, theeta1-defective mutant, TXeta1, was unaffected in growth but exhibited attenuated overall virulence, reduced tissue dissemination and colonization capacity, and impaired ability to invade flounder lymphocytes and to block the immune response of host cells. The lost virulence of TXeta1 was restored when a functionaleta1gene was reintroduced into the strain. Western blot and immunodetection analyses showed that Eta1 is localized to the outer membrane and exposed on the surface ofE. tardaand that recombinant Eta1 (rEta1) was able to interact with flounder lymphocytes. Consistent with these observations, antibody blocking of Eta1 inhibitedE. tardainfection at the cellular level. Furthermore, when used as a subunit vaccine, rEta1 induced strong protective immunity in flounder against lethalE. tardachallenge. Taken together, these results indicate that Eta1 is anin vivo-induced antigen that mediates pathogen-host interaction and, as a result, is required for optimal bacterial infection.

scholarly journals Delivery of Ferulic Acid with PEGylated Diphenylalanine Nanoparticles for Pre-arthritis Therapy

2021 ◽  
Author(s):  
Liming He ◽  
Yingchun Zeng ◽  
Xianyan Qin ◽  
Lihua Pan ◽  
Tao Chen ◽  
...  
Keyword(s):  
Ferulic Acid ◽  
Late Stage ◽  
Therapeutic Efficacy ◽  
Inflammatory Diseases ◽  
Early Stage ◽  
Therapeutic Outcomes ◽  
Anti Inflammatory ◽  
Poly Ethylene ◽  
Arthritic Joints

Abstract Background: In the therapy of rheumatoid arthritis (RA), treatment starting at the late stage of disease is probably associated with a worse disease outcome. Thus, blocking the RA developments at the early stage of inflammation with efficacious and safe agents might present a promising strategy. Ferulic acid (FA), a safe and active component extracted from Chinese medicine, shows excellent anti-inflammatory properties in various inflammatory diseases. However, the application of FA as an anti-inflammatory drug is hindered by its instability and short half-life in vivo. The aim of this study is to design a feasible drug delivery system to improve the therapeutic efficacy of FA in the treatment of RA and investigate whether treatment initiated at early stage of arthritis would effectively prevent the development of arthritis.Method: A diphenylalanine-based nanoparticle was constructed by the self-stacking of NH2-Phe-Phe-COOH and poly (ethylene glycol) methyl ether amine (PEG5k-NH2) using the glutaraldehyde (GTA) as a cross-linker. The therapeutic outcomes of treatment using FA-loaded PEGylated Phe-Phe nanoparticles were explored at both pre-arthritis stage and fully-developed arthritis stage. Results: We find that the FA-loaded PEGylated Phe-Phe nanoparticles are biocompatible and could effectively inhibit the production of reactive oxygen species in inflammatory condition. After being intravenously administrated in vivo, the FA-loaded PEGylated Phe-Phe nanoparticles show prolonged circulation time and enhanced accumulation in arthritic joints. More importantly, the pre-arthritis treatment with the FA-loaded PEGylated Phe-Phe nanoparticles can significantly block the progression of RA compared with treatment started at the late stage of arthritis.Conclusions: Our results demonstrated FA-loaded PEGylated Phe-Phe nanoparticles could greatly improve the therapeutic efficacy of FA and ultimately prevent the progression of arthritis in a low activity when applied in pre-arthritis phase. This therapeutic outcome confirmed the treatment initiated in very early disease phases is effective to prevent arthritis progression to full-blown disease.

Exploiting Anti-Inflammation Effects of Flavonoids in Chronic Inflammatory Diseases

2020 ◽  
Vol 26 (22) ◽  
pp. 2610-2619 ◽  
Author(s):  
Tarique Hussain ◽  
Ghulam Murtaza ◽  
Huansheng Yang ◽  
Muhammad S. Kalhoro ◽  
Dildar H. Kalhoro
Keyword(s):  
Oxidative Stress ◽  
Chronic Diseases ◽  
Inflammatory Diseases ◽  
Therapeutic Option ◽  
Cellular Level ◽  
Antiinflammatory Drugs ◽  
Suitable Alternative ◽  
Chronic Inflammatory Diseases

Background: Inflammation is a complex response of the host defense system to different internal and external stimuli. It is believed that persistent inflammation may lead to chronic inflammatory diseases such as, inflammatory bowel disease, neurological and cardiovascular diseases. Oxidative stress is the main factor responsible for the augmentation of inflammation via various molecular pathways. Therefore, alleviating oxidative stress is effective a therapeutic option against chronic inflammatory diseases. Methods: This review article extends the knowledge of the regulatory mechanisms of flavonoids targeting inflammatory pathways in chronic diseases, which would be the best approach for the development of suitable therapeutic agents against chronic diseases. Results: Since the inflammatory response is initiated by numerous signaling molecules like NF-κB, MAPK, and Arachidonic acid pathways, their encountering function can be evaluated with the activation of Nrf2 pathway, a promising approach to inhibit/prevent chronic inflammatory diseases by flavonoids. Over the last few decades, flavonoids drew much attention as a potent alternative therapeutic agent. Recent clinical evidence has shown significant impacts of flavonoids on chronic diseases in different in-vivo and in-vitro models. Conclusion: Flavonoid compounds can interact with chronic inflammatory diseases at the cellular level and modulate the response of protein pathways. A promising approach is needed to overlook suitable alternative compounds providing more therapeutic efficacy and exerting fewer side effects than commercially available antiinflammatory drugs.

scholarly journals High-throughput screening and rational design of biofunctionalized surfaces with optimized biocompatibility and antimicrobial activity

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Zhou Fang ◽  
Junjian Chen ◽  
Ye Zhu ◽  
Guansong Hu ◽  
Haoqian Xin ◽  
...  
Keyword(s):  
Antimicrobial Activity ◽  
High Throughput ◽  
High Throughput Screening ◽  
Rational Design ◽  
Click Reaction ◽  
Reaction Times ◽  
Great Promise ◽  
Biomaterial Surfaces

AbstractPeptides are widely used for surface modification to develop improved implants, such as cell adhesion RGD peptide and antimicrobial peptide (AMP). However, it is a daunting challenge to identify an optimized condition with the two peptides showing their intended activities and the parameters for reaching such a condition. Herein, we develop a high-throughput strategy, preparing titanium (Ti) surfaces with a gradient in peptide density by click reaction as a platform, to screen the positions with desired functions. Such positions are corresponding to optimized molecular parameters (peptide densities/ratios) and associated preparation parameters (reaction times/reactant concentrations). These parameters are then extracted to prepare nongradient mono- and dual-peptide functionalized Ti surfaces with desired biocompatibility or/and antimicrobial activity in vitro and in vivo. We also demonstrate this strategy could be extended to other materials. Here, we show that the high-throughput versatile strategy holds great promise for rational design and preparation of functional biomaterial surfaces.

scholarly journals Single Domain Antibodies as Carriers for Intracellular Drug Delivery: A Proof of Principle Study

Biomolecules ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 927
Author(s):  
Sebas D. Pronk ◽  
Erik Schooten ◽  
Jurgen Heinen ◽  
Esra Helfrich ◽  
Sabrina Oliveira ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Targeted Delivery ◽  
Single Domain ◽  
Drug Conjugates ◽  
Intracellular Drug Delivery ◽  
Internalization Rate ◽  
Single Domain Antibodies ◽  
Different Characteristics

Antibody-drug conjugates (ADCs) are currently used for the targeted delivery of drugs to diseased cells, but intracellular drug delivery and therefore efficacy may be suboptimal because of the large size, slow internalization and ineffective intracellular trafficking of the antibody. Using a phage display method selecting internalizing phages only, we developed internalizing single domain antibodies (sdAbs) with high binding affinity to rat PDGFRβ, a receptor involved in different types of diseases. We demonstrate that these constructs have different characteristics with respect to internalization rates but all traffic to lysosomes. To compare their efficacy in targeted drug delivery, we conjugated the sdAbs to a cytotoxic drug. The conjugates showed improved cytotoxicity correlating to their internalization speed. The efficacy of the conjugates was inhibited in the presence of vacuolin-1, an inhibitor of lysosomal maturation, suggesting lysosomal trafficking is needed for efficient drug release. In conclusion, sdAb constructs with different internalization rates can be designed against the same target, and sdAbs with a high internalization rate induce more cell killing than sdAbs with a lower internalization rate in vitro. Even though the overall efficacy should also be tested in vivo, sdAbs are particularly interesting formats to be explored to obtain different internalization rates.

scholarly journals Upregulations of Clcn3 and P-Gp Provoked by Lens Osmotic Expansion in Rat Galactosemic Cataract

2017 ◽  
Vol 2017 ◽  
pp. 1-8
Author(s):  
Lixia Ji ◽  
Lixia Cheng ◽  
Zhihong Yang
Keyword(s):  
Osmotic Stress ◽  
Early Stage ◽  
Lens Epithelial Cells ◽  
Anterior Capsule ◽  
Glycoprotein P ◽  
Protein Levels ◽  
P Glycoprotein ◽  
Sugar Cataract

Objective.Lens osmotic expansion, provoked by overactivated aldose reductase (AR), is the most essential event of sugar cataract. Chloride channel 3 (Clcn3) is a volume-sensitive channel, mainly participating in the regulation of cell fundamental volume, and P-glycoprotein (P-gp) acts as its modulator. We aim to study whether P-gp and Clcn3 are involved in lens osmotic expansion of galactosemic cataract.Methods and Results.In vitro, lens epithelial cells (LECs) were primarily cultured in gradient galactose medium (10–60 mM), more and more vacuoles appeared in LEC cytoplasm, and mRNA and protein levels of AR, P-gp, and Clcn3 were synchronously upregulated along with the increase of galactose concentration. In vivo, we focused on the early stage of rat galactosemic cataract, amount of vacuoles arose from equatorial area and scattered to the whole anterior capsule of lenses from the 3rd day to the 9th day, and mRNA and protein levels of P-gp and Clcn3 reached the peak around the 9th or 12th day.Conclusion. Galactosemia caused the osmotic stress in lenses; it also markedly leads to the upregulations of AR, P-gp, and Clcn3 in LECs, together resulting in obvious osmotic expansion in vitro and in vivo.

scholarly journals In vitro and In vivo Molecular Evidence for Better Therapeutic Efficacy of ABT-627 and Taxotere Combination in Prostate Cancer

2007 ◽  
Vol 67 (8) ◽  
pp. 3818-3826 ◽  
Author(s):  
Sanjeev Banerjee ◽  
Maha Hussain ◽  
Zhiwei Wang ◽  
Allen Saliganan ◽  
Mingxin Che ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Therapeutic Efficacy ◽  
Molecular Evidence

scholarly journals Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Mylène Tajan ◽  
Marc Hennequart ◽  
Eric C. Cheung ◽  
Fabio Zani ◽  
Andreas K. Hock ◽  
...  
Keyword(s):  
Therapeutic Efficacy ◽  
De Novo ◽  
Carbon Availability ◽  
Global Protein Synthesis ◽  
Enhanced Expression ◽  
One Carbon Metabolism ◽  
Amino Acid Depletion ◽  
Pathway Inhibition

AbstractMany tumour cells show dependence on exogenous serine and dietary serine and glycine starvation can inhibit the growth of these cancers and extend survival in mice. However, numerous mechanisms promote resistance to this therapeutic approach, including enhanced expression of the de novo serine synthesis pathway (SSP) enzymes or activation of oncogenes that drive enhanced serine synthesis. Here we show that inhibition of PHGDH, the first step in the SSP, cooperates with serine and glycine depletion to inhibit one-carbon metabolism and cancer growth. In vitro, inhibition of PHGDH combined with serine starvation leads to a defect in global protein synthesis, which blocks the activation of an ATF-4 response and more broadly impacts the protective stress response to amino acid depletion. In vivo, the combination of diet and inhibitor shows therapeutic efficacy against tumours that are resistant to diet or drug alone, with evidence of reduced one-carbon availability. However, the defect in ATF4-response seen in vitro following complete depletion of available serine is not seen in mice, where dietary serine and glycine depletion and treatment with the PHGDH inhibitor lower but do not eliminate serine. Our results indicate that inhibition of PHGDH will augment the therapeutic efficacy of a serine depleted diet.

A Simple Silicon Based Nitric Oxide Sensor

1999 ◽  
Author(s):  
Marcelo Bariatto ◽  
Rogerio Furlan ◽  
Koiti Arakai ◽  
Jorge J. Santiago-Aviles
Keyword(s):  
Nitric Oxide ◽  
Amperometric Detection ◽  
Cellular Level ◽  
High Yield ◽  
Sensor Calibration ◽  
Nitric Oxide Sensor ◽  
Sensor Configuration

Abstract Nitric oxide (NO) is known to mediate many beneficial physiology processes, motivating its detection in vivo as well as in vitro. Electrochemical detection provides the required cellular level determination of NO among several other techniques. In this work, electrochemical micro-sensors for both types of detection, in vivo and in vitro, were developed, exploring the silicon planar technology, which presents high yield and reliability and also permits batch fabrication. The developed in vitro sensor features eight detection sites (10 μm × 10 μm microelectrodes), for determination of nitric oxide spatial distribution or multi-species analysis. Different electrochemical methods were applied to provide sensor calibration and chemical reproducibility. For in vivo analysis, the designed structures have a needle shape (40 μm thick) and they were silicon micro-machined by using plasma etching or etch stop techniques. Different configurations were designed and implemented, containing a number of detection microelectrodes that vary from 2 to 10. The amperometric detection of both nitric oxide and nitride (NO2−) — a molecule that causes an interference — were investigated by using the in vitro micro-sensor configuration. The need of a cationic exchanger (Nafion) was demonstrated in order to provide selectivity to NO for low concentrations. Also, the developed sensor has a sensitivity of 500 A/M.cm2 and a detection limit of 10 μM.

Sign in / Sign up

Export Citation Format

Share Document